Feasibility and early toxicity of intraoperative radiotherapy for breast cancer using the papillon + system: First results
- PMID: 36353651
- PMCID: PMC9638720
- DOI: 10.1016/j.ctro.2022.10.006
Feasibility and early toxicity of intraoperative radiotherapy for breast cancer using the papillon + system: First results
Abstract
Background and purpose: Breast intra operative radiation therapy has been evaluated with different systems delivering 20-21 Gy with treatment times around 30 min. Papillon + TM Contact X-ray machine was designed to produce a 50 kVp beam with a high dose rate ≥ 15 Gy/minute. A pilot study with the first prototype was conducted in Nice.
Materials and methods: The inclusion criteria were age ≥ 60 years, unifocal ductal breast adenocarcinoma ≤ 2.5 cm, grade 1-2. Surgical local excision with sentinel node dissection was performed and the applicator was placed in the tumor bed after excision with a prescribed dose of 20 Gy. The main end point of the study was the doses measured with the Gafchromic films; two were located at the skin surface and two in the excision cavity. Secondary endpoints were early toxicity and relapse free survival.
Results: Between 10/2018 and 09/2019, 26 patients were included. Mean Gafchromic doses were 18.8 Gy ± 2 Gy at the south pole, 15.6 Gy ± 2.81 Gy at the equator and 2.5 Gy ± 1.67 Gy at the skin. With a median follow-up time of 12 months, no skin or subcutaneous toxicity > grade 2, no local relapse and no metastasis were observed.
Conclusion: This is the first phase II study testing the Papillon + tm system for breast IORT with in vivo dosimetry measurements and reassuring clinical data.
Keywords: Brachytherapy; Breast IORT; High dose rate; Papillon+ system.
© 2022 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.
Conflict of interest statement
Pr J-P Gérard declares he is medical advisor without any financial conflict for Ariane and Clerad. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures



References
-
- Hughes K.S., Schnaper L.A., Bellon J.R., Cirrincione C.T., Berry D.A., McCormick B., et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013 Jul 1;31(19):2382–2387. doi: 10.1200/JCO.2012.45.2615. Epub 2013 May 20PMID: 23690420. - DOI - PMC - PubMed
-
- Fastner G., Sedlmayer F., Widder J., Metz M., Geinitz H., Kapp K., et al. Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial.nEur. J Cancer. 2020 Mar;127(12–20) doi: 10.1016/j.ejca.2019.11.024. Epub 2020 Jan 18. - DOI - PubMed
-
- Smith B.D., Arthur D.W., Buchholz T.A., Haffty B.G., Hahn C.A., Hardenbergh P.H., et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO) Int J Radiat Oncol Biol Phys. 2009;74(4):987–1001. - PubMed
-
- Correa C1, Harris EE2, Leonardi MC3, Smith BD4, Taghian AG5, Thompson AM et al. Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Pract Radiat Oncol. 2017 Mar - Apr;7(2):73-79. 10.1016/j.prro.2016.09.007. Epub 2016 Sep 17. - PubMed
-
- Polgár C., Van Limbergen E., Pötter R., Kovács G., Polo A., Lyczek J., et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009) Radiother Oncol. 2010 Mar;94(3):264–273. doi: 10.1016/j.radonc.2010.01.014. Epub 2010 Feb 22. - DOI - PubMed
LinkOut - more resources
Full Text Sources